Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BEYFORTUS vs PORTRAZZA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
BEYFORTUS (nirsevimab) is a recombinant human monoclonal antibody that binds to the prefusion conformation of the respiratory syncytial virus (RSV) F protein, inhibiting viral entry into host cells by blocking the fusion of the viral envelope with the host cell membrane.
PORTRAZZA (necitumumab) is a recombinant human Ig G1 monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), thereby inhibiting ligand binding and subsequent activation of EGFR, leading to inhibition of downstream signaling pathways involved in cell proliferation and survival.
Prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants entering their first RSV season, and in children up to 24 months of age who remain vulnerable through their second RSV season.
First-line treatment of metastatic squamous non-small cell lung cancer (NSCLC) in combination with gemcitabine and cisplatin.
Not applicable; BEYFORTUS (nirsevimab) is indicated for prevention of respiratory syncytial virus lower respiratory tract disease in neonates and infants. No adult dose exists.
PORTRAZZA (necitumumab) is administered intravenously at a dose of 800 mg over 60 minutes on days 1 and 8 of each 21-day cycle.
Terminal elimination half-life is approximately 26.8 days in infants, supporting season-long protection after a single dose.
Terminal elimination half-life is approximately 14 days (range 10–18 days). This long half-life supports dosing every 3 weeks and allows sustained receptor blockade.
Nirsevimab is degraded via catabolic pathways into small peptides and amino acids.
Metabolism of necitumumab has not been fully characterized. As a monoclonal antibody, it is expected to be degraded into small peptides and amino acids via general protein catabolic pathways.
Beyfortus (nirsevimab) is eliminated primarily via catabolism to small peptides and amino acids. No specific data on renal or biliary excretion; expected to undergo proteolytic degradation with minimal renal or fecal elimination of intact drug.
Necitumumab is an Ig G1 monoclonal antibody; elimination occurs via intracellular catabolism, with no significant renal or biliary excretion. No specific percentage of elimination via renal or fecal routes is established.
Protein binding is approximately 99.5%, primarily to albumin.
Necitumumab is a monoclonal antibody; target-mediated binding to EGFR occurs, but nonspecific plasma protein binding is negligible. No specific protein binding percentage is reported.
Volume of distribution is approximately 4.5 L in infants (mean Vd ≈ 0.3 L/kg), indicating distribution primarily in plasma and interstitial fluid.
Volume of distribution at steady state is approximately 5.8 L (range 4.7–7.1 L), suggesting distribution primarily in the vascular space and minimal extravascular distribution.
Bioavailability after intramuscular injection is approximately 70-80% (absolute bioavailability not established; relative to IV data).
Intravenous: 100% (not applicable to other routes).
No dosage adjustment required for renal impairment; nirsevimab is a monoclonal antibody not renally cleared.
No dose adjustment is recommended for patients with mild to moderate renal impairment. There is no data for severe renal impairment (Cr CL <30 m L/min) or end-stage renal disease.
No dosage adjustment required for hepatic impairment; nirsevimab is a monoclonal antibody not hepatically metabolized.
No formal studies have been conducted in patients with hepatic impairment. No dose adjustment is recommended for mild hepatic impairment (Child-Pugh A). Use caution in moderate to severe hepatic impairment due to lack of data.
Neonates and infants weighing <5 kg: 50 mg intramuscular (IM) single dose; infants weighing ≥5 kg: 100 mg IM single dose. Administer during RSV season.
Safety and effectiveness in pediatric patients have not been established.
Not indicated for geriatric population; no dosing recommendations available.
No specific dose adjustment is recommended for elderly patients. Clinical studies included patients aged 65 years and older; no overall differences in safety or efficacy were observed compared to younger patients.
No black box warning.
No black box warnings.
Hypersensitivity reactions including anaphylaxis have been reported.,Use caution in patients with thrombocytopenia or any coagulation disorder due to risk of bleeding from intramuscular injection.
Cardiopulmonary arrest and/or sudden death occurred in 3% of patients receiving necitumumab in combination with gemcitabine and cisplatin; monitor electrolytes and consider withholding for severe electrolyte abnormalities.,Arterial thromboembolic events (ATEs) occurred in 5% of patients; permanently discontinue for serious ATEs.,Venous thromboembolic events (VTEs) including pulmonary embolism occurred; permanently discontinue for life-threatening VTEs.,Hemolytic-uremic syndrome (HUS) reported; discontinue if HUS is suspected.,Dermatologic toxicities including rash, dry skin, and pruritus; monitor and manage accordingly.,Infusion-related reactions; interrupt or discontinue for severe reactions.,Hypomagnesemia occurred in 83% of patients; monitor magnesium, calcium, and potassium prior to each dose.,Embryofetal toxicity: can cause fetal harm; advise females of reproductive potential of effective contraception.
History of serious hypersensitivity reaction to nirsevimab or any component of the formulation.
No known contraindications from the manufacturer.
No known food interactions. BEYFORTUS is administered by intramuscular injection and does not interact with dietary components.
No specific food interactions have been identified with necitumumab. However, maintain adequate hydration and nutrition. Grapefruit and other CYP3A4 inhibitors are not expected to interact since necitumumab is a monoclonal antibody cleared via proteolysis.
BEYFORTUS (nirsevimab) is a human monoclonal antibody against respiratory syncytial virus. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, no adverse developmental effects were observed in pregnant rabbits or cynomolgus monkeys at doses up to 10 times the human clinical exposure. However, because monoclonal antibodies are transported across the placenta in increasing amounts as pregnancy progresses (especially in the third trimester), potential fetal exposure may occur. Based on limited data, the risk of major birth defects and miscarriage is unknown but expected to be low due to the Ig G1 nature and lack of known teratogenic signal.
Portrazza (necitumumab) is an Ig G1 monoclonal antibody. Ig G molecules are actively transported across the placenta during the third trimester, potentially exposing the fetus to therapeutic concentrations. There are no adequate and well-controlled studies in pregnant women. Based on its mechanism of action (EGFR inhibition), there is a risk of fetal harm, including developmental abnormalities and fetal loss. Women of reproductive potential should use effective contraception during treatment and for at least 3 months after the last dose.
There are no data on the presence of nirsevimab in human milk, effects on the breastfed infant, or effects on milk production. Nirsevimab is a human monoclonal antibody (Ig G1) and is expected to be excreted into human milk in small amounts due to the high molecular weight and limited transfer via the neonatal Fc receptor. The M/P ratio has not been determined. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for BEYFORTUS and any potential adverse effects on the breastfed infant from the drug or underlying condition.
It is not known whether necitumumab is excreted in human milk. Human Ig G is known to be present in milk, but the amount is generally low. Due to the potential for serious adverse reactions in nursing infants, advise women not to breast-feed during treatment and for at least 3 months after the last dose. M/P ratio is unknown.
No dosing adjustments are required for BEYFORTUS during pregnancy. Pregnancy-related physiological changes (e.g., increased plasma volume, altered renal clearance) are not expected to significantly affect the pharmacokinetics of a monoclonal antibody administered intramuscularly, as nirsevimab has a long half-life and is not renally excreted. The standard single dose of 50 mg (for infants <5 kg) or 100 mg (for infants ≥5 kg) is recommended regardless of pregnancy status.
No specific dosing adjustments for pregnancy are established. However, physiological changes during pregnancy (e.g., increased plasma volume, altered renal clearance) may affect pharmacokinetics. Currently, no dose modification is recommended due to lack of data; however, caution is advised, and treatment should only be used if the potential benefit justifies the potential risk to the fetus.
BEYFORTUS (nirsevimab) is a recombinant human monoclonal antibody for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. It is administered as a single intramuscular injection, typically 50 mg for infants <5 kg and 100 mg for infants ≥5 kg. It is not a treatment for active RSV infection. It does not interfere with live attenuated vaccines; however, administration with other injectable vaccines at different sites is acceptable. Do not administer to infants with a history of severe hypersensitivity to nirsevimab or any excipients. Efficacy has not been established in infants with a history of RSV infection.
PORTRAZZA (necitumumab) is a human Ig G1 monoclonal antibody targeting EGFR. Prior to initiation, confirm EGFR expression in squamous non-small cell lung cancer. Premedicate with H1 antagonists to reduce infusion-related reactions. Monitor for hypomagnesemia, which can occur weeks after treatment; replete as needed. Avoid use in patients with a history of severe infusion reactions to other EGFR inhibitors.
This vaccine is given as a single shot to prevent serious RSV disease in your infant.,It is not a treatment for active RSV infection; if your infant has RSV symptoms, inform the healthcare provider.,Common side effects include injection site reactions, rash, and fever. Contact your provider if these persist or worsen.,Inform the healthcare provider of any allergic reactions or bleeding disorders before administration.,Your infant can still receive other vaccines as scheduled.
Inform your doctor if you experience severe skin rash, diarrhea, or infusion reactions during treatment.,Report any signs of low magnesium such as muscle cramps, numbness, or irregular heartbeat.,Avoid sun exposure and use broad-spectrum sunscreen SPF 50+; this drug increases photosensitivity.,Do not receive live vaccines while on PORTRAZZA.,Use effective contraception during treatment and for 3 months after the last dose if you are of childbearing potential.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BEYFORTUS vs PORTRAZZA, answered by our medical review team.
BEYFORTUS is a Monoclonal Antibody for RSV Prophylaxis that works by BEYFORTUS (nirsevimab) is a recombinant human monoclonal antibody that binds to the prefusion conformation of the respiratory syncytial virus (RSV) F protein, inhibiting viral entry into host cells by blocking the fusion of the viral envelope with the host cell membrane.. PORTRAZZA is a Antineoplastic Monoclonal Antibody that works by PORTRAZZA (necitumumab) is a recombinant human Ig G1 monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), thereby inhibiting ligand binding and subsequent activation of EGFR, leading to inhibition of downstream signaling pathways involved in cell proliferation and survival.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BEYFORTUS and PORTRAZZA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BEYFORTUS is: Not applicable; BEYFORTUS (nirsevimab) is indicated for prevention of respiratory syncytial virus lower respiratory tract disease in neonates and infants. No adult dose exists.. The standard adult dose of PORTRAZZA is: PORTRAZZA (necitumumab) is administered intravenously at a dose of 800 mg over 60 minutes on days 1 and 8 of each 21-day cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BEYFORTUS and PORTRAZZA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BEYFORTUS is classified as Category C. BEYFORTUS (nirsevimab) is a human monoclonal antibody against respiratory syncytial virus. There are no adequate and well-controlled studies in pregnant women. In animal reproducti. PORTRAZZA is classified as Category C. Portrazza (necitumumab) is an IgG1 monoclonal antibody. IgG molecules are actively transported across the placenta during the third trimester, potentially exposing the fetus to the. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.